MRNS(Delisted)
Marinus·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MRNS
Marinus Pharmaceuticals, Inc.
A pharmaceutical company that developing innovative therapeutics to treat seizure disorders
5 Radnor Corporate Center, Suite 500, 100 Matsonford Road, Radnor, PA 19087
--
Marinus Pharmaceuticals, Inc., was incorporated in Delaware on August 14, 2003. The Company is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for the treatment of epilepsy disorders, including rare hereditary epilepsy and status epilepticus, which includes the use of ZTALMY (ganaxolone). The company is developing ganaxolone for use in two formulations with different routes of administration: intravenous (IV) and oral. The different formulations are designed to maximize the potential therapeutic applications of ganaxolone in adult and pediatric patient populations, including acute and chronic care.
Company Financials
EPS
MRNS has released its 2024 Q3 earnings. EPS was reported at -0.42, versus the expected -0.41, missing expectations. The chart below visualizes how MRNS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MRNS has released its 2024 Q3 earnings report, with revenue of 8.54M, reflecting a YoY change of 16.39%, and net profit of -24.23M, showing a YoY change of 26.53%. The Sankey diagram below clearly presents MRNS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
